A seeming paradox exists during the maintenance phase of acute renal failure (ARF). On the one hand, diverse forms of acute tubular injury evoke adaptive responses that protect the kidney from further damage (so called "acquired cytoresistance"). Presumably, this protection confers a survival advantage, both at the whole organ, and whole animal, level. On the other hand, a potentially countervailing consequence of ARF is that the kidney hyper-responds to diverse Toll like receptor (TLR) ligands, most notably lipopolysaccharide (LPS). This causes exaggerated LPS- driven cytokine and chemokine (e.g., TNF-a / MCP- 1) production. As a result, profound increases in intra-renal levels of these pro-inflammatory mediators develop, potentially slowing ARF recovery. Furthermore, with cytokine efflux into renal venous blood, striking increases in circulating cytokine / chemokine levels develop. This can contribute to extra-renal tissue damage (e.g., in lung, liver, heart, and brain;i.e., "organ cross-talk"), and thus, predispose to multi-organ failure (MOF). The clinical relevance of these events is underscored by the fact that Gram negative sepsis and MOF are leading causes of death in patients with ARF. This application hypothesizes that these two ARF maintenance phase phenomena (cytoresistance;TLR hyper-responsiveness) are examples of "biologic memory": i.e., whereby one episode of renal injury 're-programs'the kidney to 'remember'the initial insult, and thus, produce altered tissue responses upon re-challenge. Over the past 3 years, the PI has tested the hypothesis that this "biologic memory" is expressed at the genomic level, and that these genomic changes help determine how the ARF kidney responds to subsequent insults. To support this concept, we have identified "activating" histone changes at specific genes that participate in both acquired cytoresistance (heme oxygenase 1, HMG CoA reductase), and the hyper-inflammatory state (TNF-a;MCP-1). During the resolution phase of ARF, the histone changes at these pro-inflammatory genes and their cognate mRNAs progressively increase. Conversely, cytoresistant gene expression progressively abates. These reciprocal shifting patterns, i.e., increasing inflammatory gene expression / decreasing cytoresistance gene expression, can delay ARF recovery. Hence, the overall aims of the proposed investigation are as follows: 1. Delineate which specific cell injury pathways (e.g., ATP depletion, oxidant stress, phospholipid hydrolysis) are the initial stimuli that trigger downstream histone alterations;2. Determine whether histone changes occur at test gene promoter regions, and whether hyper-recruitment of relevant transcription factors and of RNA polymerase II (Pol II) to them result;3. Ascertain the histone-modifying machineries that induce these histone alterations;and 4. Using the information gleaned from the above, test the mechanistic relevance of these pathways to the cytoresistance and the hyper-inflammatory states. By so doing, new insights into ischemia- induced tissue modifications, with implications for subsequent tissue injury, will result.

Public Health Relevance

This application addresses how pre-existent acute kidney injury alters how the kidney responds to further injury events. One the one hand, pre-existent injury ushers in protective mechanisms that mitigate further lethal damage;on the other hand, the injured kidney hyper-responds to inflammatory molecules, and this has implications for both the kidney and the rest of the body. This application addresses the mechanisms by which these changes occur, and how they can be altered to enhance kidney recovery.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK038432-25A1
Application #
8218964
Study Section
Pathobiology of Kidney Disease Study Section (PBKD)
Program Officer
Kimmel, Paul
Project Start
1988-03-01
Project End
2015-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
25
Fiscal Year
2012
Total Cost
$382,800
Indirect Cost
$165,300
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Zager, Richard A; Johnson, Ali C M; Becker, Kirsten (2014) Renal cortical pyruvate depletion during AKI. J Am Soc Nephrol 25:998-1012
Johnson, Ali C M; Zager, Richard A (2014) Renal cortical pyruvate as a potentially critical mediator of acute kidney injury. Nephron Clin Pract 127:129-32
Zager, Richard A; Johnson, Ali C M; Frostad, Kirsten B (2014) Rapid renal alpha-1 antitrypsin gene induction in experimental and clinical acute kidney injury. PLoS One 9:e98380
Zager, Richard A; Johnson, Ali C M; Frostad, Kirsten B (2014) Acute hepatic ischemic-reperfusion injury induces a renal cortical "stress response," renal "cytoresistance," and an endotoxin hyperresponsive state. Am J Physiol Renal Physiol 307:F856-68
Zager, Richard A (2014) Progression from acute kidney injury to chronic kidney disease: clinical and experimental insights and queries. Nephron Clin Pract 127:46-50
Zager, Richard A; Johnson, Ali C M; Andress, Dennis et al. (2013) Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury. Kidney Int 84:703-12
Ruiz, Stacey; Pergola, Pablo E; Zager, Richard A et al. (2013) Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 83:1029-41
Zager, Richard A; Johnson, Ali C; Becker, Kirsten (2013) Post-ischemic azotemia as a partial 'brake', slowing progressive kidney disease. Nephrol Dial Transplant 28:1455-62
Zager, Richard A; Johnson, Ali C M; Becker, Kirsten (2013) Renal Cortical Lactate Dehydrogenase: A Useful, Accurate, Quantitative Marker of In Vivo Tubular Injury and Acute Renal Failure. PLoS One 8:e66776
Zager, Richard A (2013) 'Biologic memory' in response to acute kidney injury: cytoresistance, toll-like receptor hyper-responsiveness and the onset of progressive renal disease. Nephrol Dial Transplant 28:1985-93

Showing the most recent 10 out of 91 publications